1. Home
  2. CRAI vs TBPH Comparison

CRAI vs TBPH Comparison

Compare CRAI & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CRA International Inc.

CRAI

CRA International Inc.

HOLD

Current Price

$147.54

Market Cap

898.0M

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$16.74

Market Cap

824.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRAI
TBPH
Founded
1965
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
898.0M
824.9M
IPO Year
1998
2013

Fundamental Metrics

Financial Performance
Metric
CRAI
TBPH
Price
$147.54
$16.74
Analyst Decision
Buy
Buy
Analyst Count
1
6
Target Price
$245.00
$18.40
AVG Volume (30 Days)
115.2K
326.3K
Earning Date
05-07-2026
05-04-2026
Dividend Yield
1.48%
N/A
EPS Growth
20.77
279.13
EPS
8.14
N/A
Revenue
$751,583,000.00
$15,386,000.00
Revenue This Year
$7.82
$8.46
Revenue Next Year
$5.14
N/A
P/E Ratio
$18.10
N/A
Revenue Growth
9.33
N/A
52 Week Low
$132.17
$10.56
52 Week High
$227.29
$21.03

Technical Indicators

Market Signals
Indicator
CRAI
TBPH
Relative Strength Index (RSI) 48.17 57.26
Support Level $142.53 $16.07
Resistance Level $166.99 $17.21
Average True Range (ATR) 6.78 0.32
MACD 0.66 0.07
Stochastic Oscillator 60.59 94.57

Price Performance

Historical Comparison
CRAI
TBPH

About CRAI CRA International Inc.

CRA International Inc is a consulting firm specializing in providing economic, financial and management consulting services. The company provides advisory services on economic and financial matters related to litigation and regulatory proceedings, and advises corporations on business and performance-related matters. Its consulting services are organized into two areas: litigation, regulatory and financial consulting, and management consulting. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. It derives revenues by providing professional and consulting services. Geographically, the maximum revenue is derived from the United States, followed by United Kingdom and other regions.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Share on Social Networks: